Last reviewed · How we verify
NCT07088393
Artificial Intelligence Diagnosis of Different Histopathological Growth Patterns of Colorectal Cancer Liver Metastasis
trial in Liver Metastases of Colorectal Cancer in 437 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2025
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 437 |
| Start date | 9 July 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Conditions studied
- Liver Metastases of Colorectal Cancer — all drugs for Liver Metastases of Colorectal Cancer →
Sponsor
Sun Yat-sen University
Who can join
Eligibility, any sex, with Liver Metastases of Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study selected cases of colorectal cancer liver metastasis patients who underwent liver metastasis tumor resection, retrieved the pathological HE sections of the metastatic lesions, and constructed a predictive model. AI software was applied to delineate different types of regions, achieving full automation of HGP prediction and constructing a predictive model. Statistical analysis was conducted on the classification of histopathological growth patterns (HGP) of liver metastasis and the survival prognosis of patients, and the differences in prognosis among different HGP classification methods were compared. This provides a new method for judging prognosis and treatment for clinical treatment of colorectal cancer liver metastasis patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07088393
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07088393 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 28 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07088393.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing